MedPath

A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease

Phase 1
Not yet recruiting
Conditions
Coronary Atherosclerotic Heart Disease
Registration Number
ITMCTR1900002589
Lead Sponsor
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Objectives: patients have coronary atherosclerotic heart disease (CAD) with high sdLDL-C.
Selection criteria:
1) Age between 18 and 80 (including 18 and 80);
2) Gender is not limited;
3) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%.
4) sdLDL-C (>= 52.6mg/dL)
5) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.

Exclusion Criteria

1) History of statin-related liver lesions and/or myopathy;
2) Patients with malignant tumors (excluding those cured);
3) Patients with serious diseases of heart, lung, kidney, brain and blood;
4) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.);
5) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period;
6) Participate in other clinical researchers at the same time;
7) Researchers think that it is not suitable for patients to participate in this study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sdLDL-C;
Secondary Outcome Measures
NameTimeMethod
TG;HDL-C;TC;LDL-C;
Âİ Copyright 2025. All Rights Reserved by MedPath